Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
December 2, 2019
~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of   Phenylephrine ~ ~ Biorphen is Now Available for Order Through Major Wholesalers ~ ~ Biorphen is Eton Pharmaceuticals’ First Commercially Available Product ~ DEER PARK, Ill. , Dec.
Read More
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
November 14, 2019
Biorphen ® Expected to Launch by End of November Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ( 3:30 p.m. CT ) DEER PARK, Ill. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and
Read More
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
November 13, 2019
DEER PARK, Ill. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation .
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.